Literature DB >> 11409570

GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells.

P Welker1, J Grabbe, T Zuberbier, A Grützkau, B M Henz.   

Abstract

GM-CSF is known primarily as a hematopoietic growth factor, but it has also been shown to inhibit mast cell differentiation in vitro. In order elucidate the mechanisms involved, we investigated the effects of GM-CSF in vitro on the differentiation of human leukemic mast cells (HMC-1 cells) and normal cord blood-derived mast cells (CBMC) under the influence of SCF, NGF, and fibroblast supernatant (FS). Under all culture conditions, GM-CSF induced a dose- and time-dependent reduction in intracellular histamine levels, tryptase activity, and numbers of cells immunoreactive for c-Kit and FcepsilonRIalpha. This effect leveled off between 10-100 ng/ml and after 4 days of culture. There was an associated decrease in mRNA expression for c-kit, FcepsilonRIalpha and tryptase. In contrast, no significant changes in the expression of the NGF receptor TrkA were noted under the same conditions. The GM-CSF receptor was found in HMC-1 cells and CBMC at both the mRNA and protein levels, but its expression decreased during culture with FS, and even more markedly during culture with GM-CSF. GM-CSF thus selectively inhibits in vitro induction and/or upregulation of all major mast cell characteristics in HMC-1 cells and CBMC irrespective of the growth factors present, and a concomitant downregulation of GM-CSF receptors can counteract these effects. GM-CSF may therefore function as a regulatory factor in mast cell growth and differentiation under normal and pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409570     DOI: 10.1007/s004030100225

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  7 in total

1.  FHL3 negatively regulates human high-affinity IgE receptor beta-chain gene expression by acting as a transcriptional co-repressor of MZF-1.

Authors:  Kyoko Takahashi; Chiyuki Matsumoto; Chisei Ra
Journal:  Biochem J       Date:  2005-02-15       Impact factor: 3.857

2.  CD34+ fibrocytes, alpha-smooth muscle antigen-positive myofibroblasts, and CD117 expression in the stroma of invasive squamous cell carcinomas of the oral cavity, pharynx, and larynx.

Authors:  Peter J Barth; Titus Schenck zu Schweinsberg; Annette Ramaswamy; Roland Moll
Journal:  Virchows Arch       Date:  2004-01-31       Impact factor: 4.064

3.  Mast cells condition dendritic cells to mediate allograft tolerance.

Authors:  Victor C de Vries; Karina Pino-Lagos; Elizabeth C Nowak; Kathy A Bennett; Carla Oliva; Randolph J Noelle
Journal:  Immunity       Date:  2011-10-28       Impact factor: 31.745

4.  Mast cells modulate transport of CD23/IgE/antigen complex across human intestinal epithelial barrier.

Authors:  Ya-Hong Tu; Christine Oluwole; Stevie Struiksma; Mary H Perdue; Ping-Chang Yang
Journal:  N Am J Med Sci       Date:  2009-06

5.  GM-CSF Inhibits c-Kit and SCF Expression by Bone Marrow-Derived Dendritic Cells.

Authors:  Amairelys Belen Barroeta Seijas; Sonia Simonetti; Sara Vitale; Daniele Runci; Angela Caterina Quinci; Alessandra Soriani; Mattia Criscuoli; Irene Filippi; Antonella Naldini; Federico Maria Sacchetti; Umberto Tarantino; Francesco Oliva; Eleonora Piccirilli; Angela Santoni; Francesca Di Rosa
Journal:  Front Immunol       Date:  2017-02-16       Impact factor: 7.561

6.  High abundances of neurotrophin 3 in atopic dermatitis mast cell.

Authors:  David Quarcoo; Tanja C Fischer; Nora Peckenschneider; David A Groneberg; Pia Welker
Journal:  J Occup Med Toxicol       Date:  2009-04-22       Impact factor: 2.646

7.  Blockade of mast cell activation reduces cutaneous scar formation.

Authors:  Lin Chen; Megan E Schrementi; Matthew J Ranzer; Traci A Wilgus; Luisa A DiPietro
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.